iX Biopharma Ltd. (SGX:42C)

iX Biopharma Income Statement

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	7.23	7.77	5.96	5.91	14.39	1.75
Revenue Growth (YoY)	3.27%	30.34%	0.78%	-58.91%	724.64%	77.16%
Cost of Revenue	5.2	5.73	4.91	3.59	2.1	2.13
Gross Profit	2.03	2.04	1.05	2.32	12.29	-0.38
Selling, General & Admin	6.53	6.69	6.71	9.04	9.46	8.3
Research & Development	1.22	1.64	1.73	2.82	2.33	2.75
Operating Expenses	7.79	8.33	8.54	11.86	11.79	11.05
Operating Income	-5.76	-6.29	-7.5	-9.54	0.5	-11.43
Interest Expense	-0.6	-0.33	-0.44	-0.27	-0.2	-0.17
Interest & Investment Income	0.02	0.02	0.03	0.01	-	0.01
Currency Exchange Gain (Loss)	0.48	-3.4	0.08	-2.77	-1.91	1.8
Other Non Operating Income (Expenses)	-0.09	-0.14	0.35	1.12	0.74	1.57
EBT Excluding Unusual Items	-5.95	-10.14	-7.47	-11.46	-0.88	-8.23
Gain (Loss) on Sale of Investments	-	-0.01	-2.51	1.74	-3.26	-
Other Unusual Items	-	-	-	0.01	0.04	-
Pretax Income	-5.95	-10.14	-9.99	-9.71	-4.1	-8.23
Income Tax Expense	0	0	0.81	-0.09	0.5	0
Earnings From Continuing Operations	-5.95	-10.14	-10.79	-9.62	-4.6	-8.23
Net Income	-5.95	-10.14	-10.79	-9.62	-4.6	-8.23
Net Income to Common	-5.95	-10.14	-10.79	-9.62	-4.6	-8.23
Shares Outstanding (Basic)	895	877	767	765	746	693
Shares Outstanding (Diluted)	895	877	767	765	746	693
Shares Change (YoY)	9.14%	14.25%	0.33%	2.51%	7.60%	7.13%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-3.81	-3.96	-6.83	-8.36	2.92	-8.91
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.01	0.00	-0.01
Gross Margin	28.05%	26.27%	17.59%	39.24%	85.41%	-21.89%
Operating Margin	-79.64%	-80.92%	-125.78%	-161.41%	3.48%	-654.96%
Profit Margin	-82.27%	-130.56%	-181.14%	-162.61%	-31.95%	-471.86%
Free Cash Flow Margin	-52.73%	-50.97%	-114.57%	-141.30%	20.31%	-510.32%
EBITDA	-5.36	-5.87	-7.08	-9.04	1.15	-10.79
EBITDA Margin	-74.12%	-75.59%	-118.88%	-152.93%	7.99%	-
D&A For EBITDA	0.4	0.41	0.41	0.5	0.65	0.64
EBIT	-5.76	-6.29	-7.5	-9.54	0.5	-11.43
EBIT Margin	-79.64%	-80.92%	-125.78%	-161.41%	3.48%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.